Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported the Phase I results from a randomized, multi-center, Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple myeloma (MM). The preliminary analysis of the safety data showed that the combination of four drugs was generally well tolerated in patients who had received no prior therapies and response rates were encouraging. These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH), held December 5-9, 2008 in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

This trial, called EVOLUTION(1), builds on positive results from previous studies of VELCADE based combinations in this setting. The presentation reported the first clinical data with the novel four-drug combination. The safety results allow the trial to proceed to Phase II, which will randomize patients to receive VcDR, VcDC or VcDCR.

Results from the 25 patients treated in this trial with VcDCR for a median of four cycles (range: 2-11 cycles), which were presented by Shaji Kumar, M.D., Mayo Clinic, showed:

-- The maximum tolerated dose of cyclophosphamide in the VcDCR regimen was not reached. The recommended doses for the Phase II portion of the trial include 500 mg/m(2) of cyclophosphamide, the highest planned dose, 1.3 mg/m(2) of VELCADE, 40 mg of dexamethasone and 15 mg of lenalidomide.

-- The only two dose-limiting toxicities reported were febrile neutropenia and reactivation of the Herpes Zoster virus infection.

-- The overall rate of serious adverse events (AEs) was 40 percent. The most common treatment-emergent AEs were constipation (64 percent), fatigue
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... last Thursday, August 14, 2014, has closed.  The three-year ... at $7.30 per share of common stock.  The investors ... purchase up to an additional 30% of these notes ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
... Epiphany Biosciences announced,today, the initiation of a ... treatment and management of acute infectious,mononucleosis. Currently, there ... debilitating condition or any other disease caused by,the ... broad spectrum of anti-viral activity,including inhibition of viral ...
... SAN FRANCISCO, Calif., Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... (NYSE: PFE ), has begun a Phase 1 ... syk kinase inhibitor, R343,for the treatment of allergic asthma. ... Under the terms of the companies, 2005 collaboration ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/20/2014)... 20, 2014 Biocide Systems is ... Wrench Advisors as a consultant and partner for ... accounts. , As Wrench Advisors explains on its ... your organization plan and execute programs by leveraging ... channels. Our experience developing joint venture partnerships and ...
(Date:8/20/2014)... 2014 In its latest blog post, ... program that gets clients off to a great start and ... in, is highlighting an important and possibly life-changing – perhaps ... who wants to understand the insidious nature of drug abuse: ... that drug abuse targets a certain socioeconomic group, such as ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The award-winning ... (ACPS), has expanded its presence throughout Houston to a ... Eye Institute and Laser Center building. ACPS plastic surgeon ... step forward for ACPS, which has risen to become ... surgery practices in the state since its establishment in ...
(Date:8/20/2014)... August 20, 2014 Texas Medical Research Associates ... The study will help test the effectiveness of a new ... high cholesterol may be eligible to participate in the study. ... in the blood can lead to cardiovascular disease, the no. ... can help reduce the risk of heart disease and stroke. ...
(Date:8/20/2014)... -- White, straight women are much more likely to ... women, a new study finds. Researchers examined data ... 44, who took part in polls in 2002 and ... Family Growth study. In the first poll, 13 ... for infertility. This ranged from getting advice from doctors ...
Breaking Medicine News(10 mins):Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:Texas Medical Research Associates Announce New Study 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2
... , TUESDAY, April 17 (HealthDay News) -- A group of ... indicators of your chances of living to age 70 than ... challenge the long-held belief that race or the region of ... how long you may live, according to researchers from Stanford ...
... The increasing globalization of the drug supply ... and diversion of medicines, growth of illegal Internet ... into the supply chain. As pharmaceutical companies, regulatory ... determine the best approaches to securing increasingly complex ...
... Randy Dotinga HealthDay Reporter , TUESDAY, April 17 ... value of proton therapy, an expensive new kind of radiation ... the treatment instead of the standard radiation therapy were more ... There also did not appear to be any extra benefit ...
... SEATTLE Larry Corey, M.D., president and director of Fred ... the American Academy of Arts and Sciences, one of the ... centers. , "I,m extremely honored to be in the same ... science, medicine and the arts," Corey said. "I,m also very ...
... April 17 (HealthDay News) -- New research adds to the ... plaques, the brain-clogging fragments that have been associated with Alzheimer,s ... Berlin, researchers report that they were able to use a ... brains of patients whose Alzheimer,s was confirmed after death. ...
... In an analysis of three different types ... cancer, compared with conformal radiation therapy, intensity-modulated radiation ... gastrointestinal adverse effects, hip fractures, and receipt of ... proton therapy was associated with more gastrointestinal adverse ...
Cached Medicine News:Health News:Social Factors May Affect Lifespan More Than Race, Location 2Health News:Global, common approach to pharmaceutical supply chain integrity the focus of workshop 2Health News:Global, common approach to pharmaceutical supply chain integrity the focus of workshop 3Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 2Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 3Health News:Hutchinson Center president elected to American Academy of Art and Sciences 2Health News:Hutchinson Center president elected to American Academy of Art and Sciences 3Health News:New Method to Reveal Alzheimer's Marker Shows Promise 2Health News:Study examines adverse effects among different radiation therapies for prostate cancer 2Health News:Study examines adverse effects among different radiation therapies for prostate cancer 3
... 1100RS Spectrophotometers are simple, ... for use in many ... educational, clinical, industrial and ... COD vial holders, Windows ...
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... Darkfield Quebec Colony Counter allows the user ... choice of models allows for digital counting or ... over the standard lens increasing magnification to 3.0X. ... lens to be raised or lowered. The lens ...
Medicine Products: